Suppr超能文献

相似文献

1
Post-randomization Biomarker Effect Modification Analysis in an HIV Vaccine Clinical Trial.
J Causal Inference. 2020;8(1):54-69. doi: 10.1515/jci-2019-0022. Epub 2020 Jul 25.
6
Inference on treatment effect modification by biomarker response in a three-phase sampling design.
Biostatistics. 2020 Jul 1;21(3):545-560. doi: 10.1093/biostatistics/kxy074.
7
SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION.
Ann Appl Stat. 2022 Sep;16(3):1774-1794. doi: 10.1214/21-aoas1566. Epub 2022 Jul 19.
9
Invited commentary on Pearl and principal stratification.
Int J Biostat. 2011 Aug 13;7(1):1-15. doi: 10.2202/1557-4679.1359.
10
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.
Ann Appl Stat. 2008 Mar;2(1):386-407. doi: 10.1214/07-AOAS132.

引用本文的文献

3
Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality.
PLOS Glob Public Health. 2023 Sep 1;3(9):e0001989. doi: 10.1371/journal.pgph.0001989. eCollection 2023.
4
SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION.
Ann Appl Stat. 2022 Sep;16(3):1774-1794. doi: 10.1214/21-aoas1566. Epub 2022 Jul 19.
5
Death or survival, which you measure may affect conclusions: A methodological study.
Health Sci Rep. 2022 Oct 25;5(6):e905. doi: 10.1002/hsr2.905. eCollection 2022 Nov.
6
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.
J Clin Invest. 2019 Nov 1;129(11):4838-4849. doi: 10.1172/JCI126391.

本文引用的文献

1
Identification and estimation of causal effects with outcomes truncated by death.
Biometrika. 2017 Sep;104(3):597-612. doi: 10.1093/biomet/asx034. Epub 2017 Jul 11.
3
COMPASS identifies T-cell subsets correlated with clinical outcomes.
Nat Biotechnol. 2015 Jun;33(6):610-6. doi: 10.1038/nbt.3187. Epub 2015 May 25.
4
Nonparametric Bounds and Sensitivity Analysis of Treatment Effects.
Stat Sci. 2014 Nov;29(4):596-618. doi: 10.1214/14-STS499.
5
Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints.
Stat Med. 2015 Feb 10;34(3):381-95. doi: 10.1002/sim.6349. Epub 2014 Oct 28.
6
Identification and estimation of survivor average causal effects.
Stat Med. 2014 Sep 20;33(21):3601-28. doi: 10.1002/sim.6181. Epub 2014 May 29.
7
Sharpening bounds on principal effects with covariates.
Biometrics. 2013 Dec;69(4):812-9. doi: 10.1111/biom.12103. Epub 2013 Nov 18.
8
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.
9
Design and estimation for evaluating principal surrogate markers in vaccine trials.
Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验